Mayo Clinic specialists are advising caution for adults over 60 using GLP-1 medications for weight loss due to risks of muscle loss and malnutrition.
These medications, which include Ozempic® and Wegovy®, offer significant weight-reduction benefits but can lead to frailty in older populations. For patients in this age bracket, losing lean muscle mass can compromise physical independence and increase the risk of injury.
Dr. Christina Chen and Dr. Andres Acosta, a Mayo Clinic obesity specialist, said these challenges on the Aging Forward podcast. They said that while GLP-1 drugs are effective for weight loss, the biological impact on older bodies differs from that of younger patients. The primary concern is the potential for rapid weight loss to include the depletion of essential muscle tissue.
Maintaining physical function is critical as patients age. "The importance of preserving strength, physical function, and lean mass generally increases with age," said the CEO of the American Council on Exercise.
Clinical data highlights the potency of these drugs. In one VA study, 201 veterans were prescribed semaglutide [1]. After a follow-up period of one year, the study indicated that various health markers had improved [2]. Individual cases show even more dramatic results; one patient, Jennifer Kirtley, reported losing 180 pounds [3] and reaching a clothing size six [4].
Despite these successes, the Mayo Clinic experts said that clinicians must closely monitor older adults to prevent malnutrition. They said that weight loss should be managed alongside nutritional support and strength training to ensure that the weight lost is primarily fat rather than muscle.
Because these drugs affect appetite and digestion, older adults may struggle to consume enough protein and calories to maintain their lean mass. This creates a clinical paradox where the drug treats obesity but potentially introduces frailty, a condition characterized by weakness and slow muscle recovery.
“"The importance of preserving strength, physical function, and lean mass generally increases with age"”
The use of GLP-1 agonists in the elderly represents a shift in obesity treatment that requires a multidisciplinary approach. While the drugs effectively lower weight and improve systemic health markers, the risk of sarcopenia—age-related muscle loss—could offset these gains by increasing the risk of falls and disability. For the medical community, this means that prescribing these drugs to patients over 60 must be coupled with strict protein intake monitoring and resistance exercise to preserve mobility.
